Videos

The two videos below were recorded at the Lung Summit on 18th November 2020, a promotional meeting organised and funded by AstraZeneca.

Genomics and proteomics
of lung cancer

Patient optimisation throughout the SIII NSCLC treatment pathway

PREVIOUS
Learn about the Interactive Case Studies and method
of administration for IMFINZI

SEE INTERACTIVE CASE STUDIES
patients_profile
patients_profile
posology
posology

NEXT
There is an unmet need for patients with Stage III NSCLC1,2
LEARN MORE ABOUT NSCLC

CBC: complete blood count; COPD: chronic obstructive pulmonary disease; CRT: chemoradiation therapy; ECOG: Eastern Cooperative Oncology Group; FEV1: forced expiratory volume in one second; LABA: long-acting beta-agonist; LFT: liver function test; NSCLC: non-small cell lung cancer; PFT: pulmonary function test; WHO: World Health Organization

Reference: 1. Draft IMFINZI Summary of Product Characteristics. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018. 

 

Loading......

References: 1. Postmus PE, Kerr KM, Oudkerk M, et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21. 2. Hanna N. Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New? Am Soc Clin Oncol Educ Book. 2015:e442-e447.